Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.

By P. Moayyedi, Michael G. Surette, Peter T. Kim, J. Libertucci, M. Wolfe, Catherine Onischi, D. Armstrong, J. Marshall, Z. Kassam, W. Reinisch and 1 more. Gastroenterology, 2015

1,411 citations recorded by the source corpus.

Subfields: Gastroenterology, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/daa0d953daf9175297d09aae1326e4e1b9a8e036

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

In Infectious Diseases

In Molecular Biology

Citations in the corpus

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. (2016, background): “The era of probiotics and microbiotherapy has come of age with the emergence of inflammatory disorders caused by an overt deviation of the gut microbiome (Cotillard et al., 2013; Kassam et al., 2013; Le Chatelier et al., 2013; Moayyedi et al., 2015).”
Factors affecting the composition of the gut microbiota, and its modulation (2019, background): “In 2015, Moayyedi and colleagues described the super-donor effected on the efficacy of FMT for inducing clinical remission in patients with ulcerative colitis (Moayyedi et al., 2015).”
Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome (2019, background): “Similarly, a randomized trial including approximately 70 UC patients conducted by Moayyedi and colleagues demonstrated that FMT was safe and induced disease remission in more patients compared to placebo [108].”
The gut microbiota and host health: a new clinical frontier (2015, background): “77 There are unanswered questions regarding mode of delivery, frequency of delivery and optimal donor/host characteristics.”